Company Filing History:
1 out of 3 
1 out of 832,912 Years Active: 2011
Title: **Miwa Morita: Pioneering Cancer Treatment with Anti-IgSF4 Antibody**
Introduction
Miwa Morita, based in Toyoake, Japan, is a notable inventor who has made significant contributions to the field of cancer research. With a focus on developing innovative solutions, Morita has been instrumental in creating a groundbreaking patent aimed at improving cancer diagnosis and treatment.
Latest Patents
The patent held by Miwa Morita is titled "Anti-IgSF4 antibody and utilization of the same." This invention is designed to clarify a molecule suitable for targeting in the treatment and diagnosis of cancer. Specifically, Morita's research highlights IgSF4, a molecule uniquely expressed in lung cancer cells. By employing an antibody to treat IgSF4, Morita's invention activates Antibody-Dependent Cellular Cytotoxicity (ADCC), showcasing the potential for this anti-IgSF4 antibody to serve as an effective therapeutic agent in combating cancer.
Career Highlights
Throughout her career, Miwa Morita has been associated with various organizations, including the Institute for Antibodies Co., Ltd. Her work within these institutions has been marked by a commitment to advancing medical research and developing innovative treatment strategies. Morita's patent reflects not only her expertise but also her dedication to finding solutions that can significantly impact cancer therapy.
Collaborations
Miwa Morita has collaborated with notable colleagues in her field, such as Yoshikazu Kurosawa and Yasushi Akahori. Together, they have contributed to research and developments that push the boundaries of current medical knowledge, particularly in the area of antibody-related therapies.
Conclusion
Miwa Morita stands out as a remarkable inventor in the realm of medical innovation, with her Anti-IgSF4 antibody patent promising new avenues for treating and diagnosing cancer. Her ongoing collaboration with esteemed professionals further emphasizes her commitment to the advancement of cancer research. The potential impact of her work could lead to significant improvements in patient outcomes and therapeutic strategies.